Open AccessAn Engineered Arginase FC Protein Inhibits Tumor GrowthIn VitroandIn Vivo
Author(s) -
Lihua Li,
Yan Wang,
Jun Chen,
Bi Cheng,
Jiehua Hu,
Yuehua Zhou,
Xin Gao,
Liucun Gao,
Xifan Mei,
Meiyan Sun,
Zhuomei Zhang,
Haifeng Song
Publication year - 2013
Publication title -
evidence-based complementary and alternative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 90
eISSN - 1741-4288
pISSN - 1741-427X
DOI - 10.1155/2013/423129
Subject(s) - arginase , arginine deiminase , in vivo , arginine , in vitro , argininosuccinate synthase , cancer research , fusion protein , cell growth , enzyme , biochemistry , chemistry , biology , amino acid , recombinant dna , gene , microbiology and biotechnology
Arginine is a semiessential amino acid required for the growth of melanoma and hepatocellular carcinoma, and the enzymatic removal of arginine by pegylated arginine deiminase (ADI) or arginase is being tested clinically. Here, we report a genetically engineered arginase FC fusion protein exhibiting a prolonged half-life and enhanced efficacy. The use of this enzyme to treat different tumor lines both inhibited cell proliferation and impaired cellular migration in vitro and in vivo . Our data reinforce the hypothesis that nutritional depletion is a key strategy for cancer treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom